Advertisement
Advertisement
GALT
Galectin Therapeutics Inc.
2.31
USDSponsored
-0.12
-5.02%
Apr 10, 15:59 UTC -4
Closed
After-Market
2.27
-0.03
-1.43%
GALT Earnings Reports
Positive Surprise Ratio
GALT beat 30 of 41 last estimates.
73%
Next Report
Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.06
Implied change from Q4 25 (Revenue/ EPS)
--
/-25.00%
Implied change from Q1 25 (Revenue/ EPS)
--
/-60.00%
Galectin Therapeutics Inc. earnings per share and revenue
On Mar 31, 2026, GALT reported earnings of -0.08 USD per share (EPS) for Q4 25, beating the estimate of -0.10 USD, resulting in a 21.57% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.29% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.06 USD, with revenue projected to reach -- USD, implying an decrease of -25.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Lexeo Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.32
Actual
-$0.27
Surprise
+15.84%
AleAnna, Inc. Class A Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-Actual
$0.00
Surprise
-
Unicycive Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.48
Actual
-$0.81
Surprise
-69.64%
Cardiol Therapeutics Inc. Class A Common Shares
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.07
Surprise
+14.22%
Centessa Pharmaceuticals plc - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.48
Surprise
-23.58%
Actinium Pharmaceuticals, Inc
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.20
Surprise
-5.04%
Scienture Holdings, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.28
Actual
-$0.11
Surprise
+61.48%
Jupiter Neurosciences, Inc. Common Stock
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.06
Surprise
+6.16%
Reviva Pharmaceuticals Holdings, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.19
Actual
-Surprise
-
Galmed Pharmaceuticals Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.52
Actual
-$0.80
Surprise
-53.79%
FAQ
What were Galectin Therapeutics Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Galectin Therapeutics Inc. reported EPS of -$0.08, beating estimates by 21.57%, and revenue of $0.00, 0% as expectations.
How did the market react to Galectin Therapeutics Inc.'s Q4 2025 earnings?
The stock price moved down -4.29%, changed from $2.80 before the earnings release to $2.68 the day after.
When is Galectin Therapeutics Inc. expected to report next?
The next earning report is scheduled for May 13, 2026.
What are the forecasts for Galectin Therapeutics Inc.'s next earnings report?
Based on --
analysts, Galectin Therapeutics Inc. is expected to report EPS of -$0.06 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement